| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
As a stable isotope-labeled internal standard, Entacapone-d10 does not have a primary pharmacological target in bioanalytical contexts. The unlabeled parent compound, entacapone, is a reversible, selective, and peripherally acting inhibitor of catechol-O-methyltransferase (COMT). It has IC50 values of 10, 20, and 160 nM for rat duodenum, rat liver, and human liver COMT, respectively.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Entacapone is a reversible and selective inhibitor of catechol-O-methyltransferase (COMT). It acts primarily in the periphery, as it does not readily cross the blood-brain barrier. By inhibiting COMT, it prevents the conversion of levodopa (L-DOPA) to 3-O-methyldopa (3-OMD), thereby increasing the bioavailability of L-DOPA to the brain when used as an adjunct to levodopa therapy for Parkinson‘s disease. |
| ln Vivo |
Entacapone is approved as an adjunct to levodopa/carbidopa therapy for the treatment of Parkinson‘s disease. By inhibiting peripheral COMT, it increases the plasma half-life and bioavailability of levodopa, leading to more sustained plasma concentrations and reduced “off-time” for patients experiencing motor fluctuations. The deuterated standard is not used in vivo but is used for measuring entacapone levels in PK studies.
|
| Enzyme Assay |
Entacapone-d10 is not used in non-cellular enzyme assays as a test compound. Instead, it is used as an internal standard. A known, fixed amount of the deuterated internal standard is spiked into a biological sample (e.g., plasma, urine, tissue homogenate) containing unlabeled entacapone. The sample is processed (e.g., protein precipitation, liquid-liquid extraction) and then analyzed by LC-MS/MS.
|
| Cell Assay |
No cell-based experiments are performed with the deuterated standard. For studying the pharmacology of unlabeled entacapone, cells expressing COMT (e.g., human liver microsomes or hepatocytes) are used. The cells or microsomes are incubated with varying concentrations of entacapone, a COMT substrate (e.g., epinephrine or dihydroxybenzoic acid), and the methyl donor S-adenosyl-L-methionine. The production of the methylated metabolite is measured by HPLC-ECD to calculate the IC50 for COMT inhibition.
|
| Animal Protocol |
A standard in vivo protocol for measuring the pharmacokinetics of entacapone involves administering unlabeled entacapone to healthy volunteers or rats. Blood samples are collected at various time points post-dose. A constant, known amount of Entacapone-d10 is spiked into each plasma sample as an internal standard. Following protein precipitation, samples are analyzed by LC-MS/MS to quantify the unlabeled entacapone concentration over time.
|
| ADME/Pharmacokinetics |
Entacapone-d10 is chemically identical to the analyte (entacapone) except for a +10 Da mass shift due to ten deuterium atoms, resulting in virtually identical extraction recovery, chromatographic retention time, and ionization efficiency. It is stable under typical LC-MS conditions and is designed for use as an internal standard for the quantification of entacapone by GC- or LC-MS.
|
| Toxicity/Toxicokinetics |
No direct toxicological data is provided for the deuterated standard, as it is used at trace analytical levels. The unlabeled entacapone has a well-characterized clinical safety profile; its most common side effects are dopaminergic in nature (dyskinesia, nausea) and discoloration of urine (orange-red), a harmless but characteristic side effect due to its metabolism and excretion.
|
| References |
|
| Additional Infomation |
Entacapone-d10 is a critical analytical standard for meeting regulatory requirements for bioequivalence studies of entacapone-containing products. The use of a stable isotope-labeled internal standard is the gold standard for LC-MS/MS bioanalysis, ensuring the highest level of accuracy and precision. Entacapone, as COMTAN or Comtess, is a cornerstone medication for managing Parkinson‘s disease, and Entacapone-d10 supports the ongoing pharmaceutical research and quality control for this important drug.
|
| Molecular Formula |
C14H5D10N3O5
|
|---|---|
| Molecular Weight |
315.35
|
| Exact Mass |
315.163
|
| CAS # |
1185241-19-3
|
| Related CAS # |
Entacapone;130929-57-6;(E)-Entacapone-d10
|
| PubChem CID |
45039132
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
526.6±50.0 °C at 760 mmHg
|
| Flash Point |
272.3±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
2.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])N(C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N)C([2H])([2H])C([2H])([2H])[2H]
|
| InChi Key |
JRURYQJSLYLRLN-YFIMXNTNSA-N
|
| InChi Code |
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+/i1D3,2D3,3D2,4D2
|
| Chemical Name |
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-bis(1,1,2,2,2-pentadeuterioethyl)prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1711 mL | 15.8554 mL | 31.7108 mL | |
| 5 mM | 0.6342 mL | 3.1711 mL | 6.3422 mL | |
| 10 mM | 0.3171 mL | 1.5855 mL | 3.1711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
